Madopar

Levodopa/Benserazide, the active ingredient in Madopar, is an antiparkinson agent presented as an oral tablet formulation for oral use. It is used to manage the motor symptoms of Parkinson's disease and related Parkinsonian syndromes by restoring dopamine levels in the brain.

GNH USA supplies Madopar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar is an antiparkinson medication indicated for conditions affecting dopaminergic pathways. - Parkinson's disease: improves motor function and reduces rigidity and bradykinesia. - Parkinsonian syndrome: alleviates symptoms when dopamine deficiency is present. - Levodopa‑responsive Parkinsonism: provides symptomatic relief in patients who respond to dopaminergic therapy.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea - Vomiting - Orthostatic hypotension - Dizziness - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Severe hypotension or syncope - Psychiatric disturbances (hallucinations, confusion) - Cardiac arrhythmias - Neuroleptic malignant syndrome (very rare)

When prescribing Madopar, clinicians should consider several safety measures. - Dose titration: start with the lowest effective dose and increase gradually. - Monitor blood pressure: watch for orthostatic hypotension, especially after the first dose. - Assess renal and hepatic function: adjust dosing in impaired patients. - Avoid abrupt discontinuation: taper to prevent withdrawal symptoms. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at room temperature: keep in the original container, protect from moisture.

Madopar can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis. - Pyridoxine (vitamin B6) at high doses: reduces levodopa efficacy. - Antipsychotics that block dopamine receptors (e.g., haloperidol): antagonize therapeutic effect.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure lowering. - Selective serotonin reuptake inhibitors (SSRIs): may increase serotonin syndrome risk. - Iron or calcium supplements: decrease levodopa absorption; separate dosing by at least 2 hours. - High‑protein meals: compete with levodopa transport across the gut and blood‑brain barrier.